Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).

CONCLUSIONS: Palbociclib can be an effective and safe treatment option in patients with heavily pretreated endocrine-sensitive mBC, especially in those with longer PFS to previous ET. PMID: 33242755 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33242755?dopt=Abstract

Source: Breast - November 13, 2020 Category: Cancer & Oncology Authors: Manso L, Hernando C, Galán M, Oliveira M, Cabrera MA, Bratos R, Rodríguez CA, Ruiz-Borrego M, Blanch S, Llombart-Cussac A, Delgado-Mingorance JI, Álvarez-Busto I, Gallegos I, González-Cortijo L, Morales S, Aguirre E, Hernando BA, Ballesteros A, Alés- Tags: Breast Source Type: research